Chemical intervention in heparan sulphate-dependent growth factor signalling systems using engineered heparin saccharides
Lead Research Organisation:
University of Liverpool
Department Name: Sch of Biological Sciences
Abstract
Our labs have expertise in studying the structure and activities of the complex polysaccharide heparan sulphate, which is found on the surface of all cells, and in studying biological processes in cell and developmental biology. These sugars have considerable structural diversity, and bind to many specialised proteins, such as growth factors, responsible for controlling cell behaviour in all tissues. Our labs are interested in finding out more about the molecular basis for their actions and exploiting their exciting natural properties by using them as tools to chemically interfere in biological systems. In this project we are planning to exploit a new approach we have developed for creating libraries of HS sugars with diverse structures, to study the relationships between structure and activity for a number of growth factors. We will examine how differences in structure affect the ability of these sugars to alter growth factor activities in biological assays using test tube, cell and whole animal assays. This will allow us to carry out experiments in a biological system in which targeted intervention of a known pathway and its biological outcome will be conducted. We will collect and compare the data from screening assays to both determine structural specificity amongst diverse growth factors, and identify activating and inhibitory saccharide molecules for application as selective chemical intervention tools in biological systems. We will also use the information to design selected structures for full chemical synthesis and testing, with the aim of providing a supply of defined molecules for future intervention experiments. The ultimate goal will be to establish the application of engineered heparin saccharide as a powerful tool for revealing novel insights into the functional roles of specific HS sequences in regulation of biological systems. These studies will provide new information which will help us to understand how these sugar-protein interactions regulate the functions of cells. They fit into a number of areas within the broad Council remit of increasing understanding of how living organisms function (in this case, molecular interactions relevant to cell signaling and regulation) and providing knowledge which can be used to develop new technologies and products for medicine and industry.
Technical Summary
Specific sequences in heparan sulfate (HS) determine selective protein binding and regulatory properties and are thus ideally designed as one of Nature's tools for chemical intervention. However, structure-activity studies have been hampered by limited amounts of active sequences available from natural HS. We have developed novel approaches for creating libraries of heparin-based structures 'engineered' to produce a high level of structural diversity, combined with new techniques for their further separation and analysis. This approach allows large numbers of sequences to be searched for activity for the first time, providing an opportunity to develop a generic 'chemical genetics' approach for rapid exploration of structure-activity relationships in biological systems. We will exploit this opportunity by generating a library of highly diverse HS analogue saccharides by chemical modification of poly- and oligo-saccharide heparin templates. Their activity will be screened using established in vitro binding and activity assays for 3 types of growth factors / FGFs, GDNF, and VEGF / and also using relevant ex vivo and in vivo assays in model systems (angiogenesis; kidney development) and whole organisms (C elegans and zebrafish). This will allow us to assess their potential use for targeted intervention of known signaling pathways and examination of the resulting biological outcomes. The data will be collated to determine both the level of structural specificity amongst these different growth factors and to identify activating and inhibitory saccharide molecules for application as selective chemical intervention tools in biological systems. The information gained will be used to prepare saccharide-nanoprobes for testing in biological assays, and also for the design of a limited number of relevant oligosaccharide structures for direct chemical synthesis using newly developed methods (in collaboration with Prof. Geert-Jan Boons, University of Georgia). The latter would provide highly defined chemical tools for intervention in biological systems. The ultimate goal will be to establish the application of engineered heparin saccharides as a powerful tool for revealing novel insights into the functional roles of specific HS sequences in regulation of biological systems.
Organisations
- University of Liverpool (Lead Research Organisation)
- Industrial Research Ltd (Collaboration)
- UNIVERSITY OF LEICESTER (Collaboration)
- Callaghan Innovation (Collaboration)
- University of Oslo (Collaboration)
- Uppsala University (Collaboration)
- Victoria University of Wellington (Collaboration)
- University of Georgia (Collaboration)
- Georgia University (Project Partner)
- Rensselaer Polytechnic Institute (Project Partner)
Publications

Bromfield S
(2014)
Nanoscale self-assembled multivalent (SAMul) heparin binders in highly competitive, biologically relevant, aqueous media
in Chemical Science

Guimond SE
(2009)
Rapid purification and high sensitivity analysis of heparan sulfate from cells and tissues: toward glycomics profiling.
in The Journal of biological chemistry

Guimond, SE
Novel ex vivo transgenic mouse brain tissue assay for screening BACE1 inhibitors
in Nature Methods

Patey SJ
(2008)
Engineered heparins: novel beta-secretase inhibitors as potential Alzheimer's disease therapeutics.
in Neuro-degenerative diseases

Powell AK
(2010)
Generating heparan sulfate saccharide libraries for glycomics applications.
in Nature protocols

Puvirajesinghe T
(2012)
Array-Based Functional Screening of Heparin Glycans
in Chemistry & Biology

Rudd TR
(2007)
Influence of substitution pattern and cation binding on conformation and activity in heparin derivatives.
in Glycobiology

Schwörer R
(2013)
Synthesis of a targeted library of heparan sulfate hexa- to dodecasaccharides as inhibitors of ß-secretase: potential therapeutics for Alzheimer's disease.
in Chemistry (Weinheim an der Bergstrasse, Germany)

Skidmore M
(2006)
High sensitivity separation and detection of heparan sulfate disaccharides
in Journal of Chromatography A

Skidmore MA
(2010)
Disaccharide compositional analysis of heparan sulfate and heparin polysaccharides using UV or high-sensitivity fluorescence (BODIPY) detection.
in Nature protocols
Description | • We have created a novel library of compounds based on a heparin as a chemical scaffold. These "engineered heparins" are a resource that provides a unique toolkit for chemical biology studies on these complex polysaccharides relevant to diverse biological processes. • We have demonstrated complex structure-activity relationships of engineered heparin oligosaccharides in in vitro signalling systems including FGFs, VEGF, GDNF and Slit/Robo. These compounds can be used for selective activation or inhibition of these signalling events through altered binding and activation of ligand/receptor interactions. • We have tested engineered heparins in ex vivo and in vivo systems and demonstrated that they can be used for selective intervention in signalling processes. One example is selective inhibition or activation of VEGF vs FGF-stimulated angiogenesis in the chick egg CAM assay. Different engineered heparins were found to produce selective pro-angiogenic effects that could have interesting applications in wound healing and tissue engineering. • We have conducted an extensive series of experiments testing different engineered heparin oligosaccharides' ability to activate or inhibit different features of kidney development and neurite formation. Some of the oligosaccharides are promising candidates for use in renal tissue engineering, and we are currently exploring their application in this field. • We have demonstrated in zebrafish that engineered heparins differentially and specifically regulate angiogenesis in a manner consistent with interference in distinct signalling pathways responsible for formation of branched vessel structures. These compounds will be useful to further dissect the different pathways that contribute to vascular development and may have therapeutic potential. • Overall, we have found that engineered heparins represent a privileged region of bioactive chemical space, with great potential for diverse applications in complex biological systems through selective interference in multiple signalling pathways. |
Exploitation Route | Related patent developed from SCIBS compounds: Turnbull JE, Patey SJ & Yates EA. (2006) Oligosaccharide agents for treating Alzheimers disease. WO2007/138263 Patent. This patent has been licenced to a University of Liverpool spin-out company, IntelliHep Ltd (see below) for pre-clinical development. This SCIBS grant also led to a long term collaboration on development of fully synthetic heparin saccharides, with IRL Ltd, a Crown Research Institute in New Zealand (now Callaghan Innovation). A spin-out company from the University of Liverpool, IntelliHep Ltd, was developed based on commercial exploitation of chemically modified heparins for biotechnology and drug development applications. Prof Turnbull and Dr Yates were 2 of the Founder scientists. IntelliHep has licenced a patent on compounds for treating Alzheimers disease (based on BBSRC funded project grant and Follow-On Fund grant. This project also provided a platform for a DTA BBSRC CASE studentship (2007-11)with Chromatide/Spheritech (Runcorn). This project with a local biotech company was underpinned by chemically modified heparins from the SCIBS project. Stem Cell Sciences (UK Ltd), 2008-2009: a collaborative project between SCS and IntelliHep Ltd was sub-contracted in to the University (Turnbull and Murray), involving exploitation of chemically modified heparins for human stem cell growth. Prof Turnbull and Prof Fernig have also been involved as consultants on a BBSRC-funded SBRI grant to Farfield Sensors Ltd (Crewe) that involved development of smart surfaces for presentation of glycans including modified heparins in optical biosensor instrumentation. |
Sectors | Healthcare Pharmaceuticals and Medical Biotechnology |
Description | Exploitation of modified heparins in drug discovery and biotechnology applications |
First Year Of Impact | 2010 |
Sector | Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |
Title | Engineered heparins |
Description | Libraries of selectively chemically modified heparins for applications in heparin-based drug discovery. |
Type Of Material | Technology assay or reagent |
Year Produced | 2006 |
Provided To Others? | Yes |
Impact | Exploited for a number of publications and to develop drug leads for AD, malaria, ant-cancer therapeutics and spinal repair therapies. |
Title | Heparan sulphate saccharide libraries |
Description | Development of technologies for and production of complex libraries of HS saccharides |
Type Of Material | Biological samples |
Year Produced | 2006 |
Provided To Others? | Yes |
Impact | Novel discoveries of structure-activity relationships for complex HS saccharides of relevance to biological and disease processes |
Description | Animal testing of AD secretase inhibitors |
Organisation | University of Leicester |
Department | Department of Genetics |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Develeopment of novel compounds as inhibitors for the Alzheimers beta-secretase |
Collaborator Contribution | Provision of transgenic mouse models of AD |
Impact | IP and patenting + publications |
Description | Animal testing of AD secretase inhibitors |
Organisation | University of Oslo |
Department | Department of Medical Biochemistry |
Country | Norway |
Sector | Academic/University |
PI Contribution | Develeopment of novel compounds as inhibitors for the Alzheimers beta-secretase |
Collaborator Contribution | Provision of transgenic mouse models of AD |
Impact | IP and patenting + publications |
Description | Animal testing of AD secretase inhibitors |
Organisation | Uppsala University |
Department | Department of Medical Biochemistry and Microbiology |
Country | Sweden |
Sector | Academic/University |
PI Contribution | Develeopment of novel compounds as inhibitors for the Alzheimers beta-secretase |
Collaborator Contribution | Provision of transgenic mouse models of AD |
Impact | IP and patenting + publications |
Description | Development of AD therapeutics |
Organisation | Callaghan Innovation |
Department | Carbohydrate Chemistry |
Country | New Zealand |
Sector | Private |
PI Contribution | Providing target structures and bioassays |
Collaborator Contribution | Developing synthetic chemistry for BACE inhibitors and providing compounds and radiolabelled compounds |
Impact | Chem Eur J publication, further manuscripts in preparation, joint funding and IP patent submissions |
Start Year | 2008 |
Description | Development of AD therapeutics |
Organisation | Victoria University of Wellington |
Department | Ferrier Research Institute |
Country | New Zealand |
Sector | Academic/University |
PI Contribution | Providing target structures and bioassays |
Collaborator Contribution | Developing synthetic chemistry for BACE inhibitors and providing compounds and radiolabelled compounds |
Impact | Chem Eur J publication, further manuscripts in preparation, joint funding and IP patent submissions |
Start Year | 2008 |
Description | Synthetic chemistry for HS analogues |
Organisation | Callaghan Innovation |
Department | Carbohydrate Chemistry |
Country | New Zealand |
Sector | Private |
PI Contribution | Design of target molecules for synthesis and provision of bioassays for screening |
Collaborator Contribution | Development of advanced synthetic chemistry to produce heparan sulphate saccharides Major contribution in kind through New Zealand government grants to fund their chemistry development |
Impact | Publication in JACS and Chem Euro Journal and ongoing collaborations |
Description | Synthetic chemistry for HS analogues |
Organisation | Industrial Research Ltd |
Department | Glycochemistry Division |
Country | New Zealand |
Sector | Private |
PI Contribution | Design of target molecules for synthesis and provision of bioassays for screening |
Collaborator Contribution | Development of advanced synthetic chemistry to produce heparan sulphate saccharides Major contribution in kind through New Zealand government grants to fund their chemistry development |
Impact | Publication in JACS and Chem Euro Journal and ongoing collaborations |
Description | Synthetic chemistry for HS analogues |
Organisation | University of Georgia |
Country | United States |
Sector | Academic/University |
PI Contribution | Design of target molecules for synthesis and provision of bioassays for screening |
Collaborator Contribution | Development of advanced synthetic chemistry to produce heparan sulphate saccharides Major contribution in kind through New Zealand government grants to fund their chemistry development |
Impact | Publication in JACS and Chem Euro Journal and ongoing collaborations |
Description | Synthetic chemistry for HS analogues |
Organisation | Victoria University of Wellington |
Department | Ferrier Research Institute |
Country | New Zealand |
Sector | Academic/University |
PI Contribution | Design of target molecules for synthesis and provision of bioassays for screening |
Collaborator Contribution | Development of advanced synthetic chemistry to produce heparan sulphate saccharides Major contribution in kind through New Zealand government grants to fund their chemistry development |
Impact | Publication in JACS and Chem Euro Journal and ongoing collaborations |
Description | Synthetic chemistry for heparan sulfate analogues |
Organisation | Callaghan Innovation |
Country | New Zealand |
Sector | Private |
PI Contribution | International collaboration to develop synthetic chemistry for heparin/HS glycans |
Start Year | 2008 |
Title | OLIGOSACCHARIDE COMPOUNDS |
Description | The invention relates generally to oligosaccharide compounds and the use of these compounds as pharmaceuticals for treating diseases or conditions in which it is desirable to inhibit ß-secretase. |
IP Reference | WO2012121617 |
Protection | Patent application published |
Year Protection Granted | 2012 |
Licensed | No |
Impact | Still in early stage of development |
Title | PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISORDERS |
Description | A pharmaceutical composition for use in the prevention and/or treatment of a neurodegenerative disorder comprising a compound comprised of one or more disaccharide units, the or each disaccharide unit comprising a uronate moiety linked to a glucosamine moiety, wherein the 2-O atom of the uronate moiety is substituted with a hydrogen atom, the 6-O atom of the glucosamine moiety is substituted with a sulphate group and the 2-N atom of the glucosamine moiety is substituted with an atom or group other than a sulphate group. The composition is particularly preferred for use in the prevention and/or treatment of Alzheimer's disease. |
IP Reference | WO2007138263 |
Protection | Patent application published |
Year Protection Granted | 2007 |
Licensed | Yes |
Impact | IP licensed to University of Liverpool spinout IntelliHep and currently in further development |
Title | PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISORDERS |
Description | A pharmaceutical composition for use in the prevention and/or treatment of a neurodegenerative disorder comprising a compound comprised of one or more disaccharide units, the or each disaccharide unit comprising a uronate moiety linked to a glucosamine moiety, wherein the 2-O atom of the uronate moiety is substituted with a hydrogen atom, the 6-O atom of the glucosamine moiety is substituted with a sulphate group and the 2-N atom of the glucosamine moiety is substituted with an atom or group other than a sulphate group. The composition is particularly preferred for use in the prevention and/or treatment of Alzheimer's disease. |
IP Reference | WO2007138263 |
Protection | Patent granted |
Year Protection Granted | 2007 |
Licensed | Yes |
Impact | Licenced to IntelliHep Ltd, and ongoing patent costs will be paid by IntelliHep. |
Title | Saccharide libraries |
Description | Novel methodologies for producing saccharide libraries are provided as well as the libraries themselves. |
IP Reference | US2006240473 |
Protection | Patent granted |
Year Protection Granted | 2006 |
Licensed | Yes |
Impact | Licences to University of Liverpool spin out IntelliHep Ltd for exploitation. |
Company Name | IntelliHep |
Description | IntelliHep develops a precision therapeutics for diseases such as Alzheimers and cancers. |
Year Established | 2002 |
Impact | Early stage development of hit compounds as beta-secretase inhibitors for treating the underlying cause of Alzheimers disease. Option to licence IP from Liverpool University on an anticancer metastatic drug. Employment of research staff and regular funded projects sub-contracted into University labs. Collaborating with China partners on commercial applications of heparin by-products. |
Website | http://www.intellihep.com |
Description | Hosting visit to Liverpool University by local ARUK funding supporters |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | Yes |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | Regional |
Primary Audience | Supporters |
Results and Impact | Contact was invaluable in informing supporters directly about research activities supported in Liverpool by their fund raising efforts Funding supporters were able to gain insights into new potential treatments for AD, and how their funding is used for research. |
Year(s) Of Engagement Activity | 2013 |
Description | Media releases on research findings |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | University press releases on the novel Alzheimer drug hits we discovered, along with developments in synthetic chemistry of our sugars, and applications in nerve repair and cancer therapeutics International press coverage, radio interviews (Radio City Liverpool), and TV news (BBC NW Tonight). |
Year(s) Of Engagement Activity | 2006,2007,2008,2012,2013,2014 |
Description | Outreach to Business Community |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Health professionals |
Results and Impact | Article in magazine Research Intelligence by UoL Business Gateway,(see website link "Sweet Smell of Success" http://www.liv.ac.uk/researchintelligence/issue30/alzheimers.html) Dissemination of information to business community |
Year(s) Of Engagement Activity | 2007 |
URL | http://www.liv.ac.uk/researchintelligence/issue30/alzheimers.html |
Description | Public Lecture to Garston Rotary Club |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | Lecture to Garston Rotary Club Contributing the Public Understanding of Science |
Year(s) Of Engagement Activity | 2008 |
Description | Public lecture to Liverpool Soroptimists Club |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | Yes |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | Talk sparked many questions and discussion of AD and potential new drugs and diagnostics Contribution to Public Understanding of Science |
Year(s) Of Engagement Activity | 2014 |
Description | RCUK/BBSRC event: Lifelong Health: Bioscience of Ageing (at Westminster) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Policymakers/politicians |
Results and Impact | Poster highlighting discovery of new class of drugs for AD at the RCUK/BBSRC event: 2007 Lifelong Health: Bioscience of Ageing (at Westminster) Dissemination of information on research success to MPs and policymakers |
Year(s) Of Engagement Activity | 2007 |
Description | Supporting ARUK fund raising publicity with major London donor |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | Yes |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | National |
Primary Audience | Supporters |
Results and Impact | Supporters engaged directly with researcher undertaking research activity. As above |
Year(s) Of Engagement Activity | 2013 |